InterCure Ltd. (INCR)
| Market Cap | 51.98M -34.5% |
| Revenue (ttm) | 84.76M +13.1% |
| Net Income | -11.20M |
| EPS | -0.21 |
| Shares Out | 54.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,205 |
| Open | 0.9383 |
| Previous Close | 0.9600 |
| Day's Range | 0.9383 - 0.9600 |
| 52-Week Range | 0.6800 - 1.7700 |
| Beta | 0.57 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2026 |
About INCR
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Financial Performance
In 2025, InterCure's revenue was 270.20 million, an increase of 13.13% compared to the previous year's 238.85 million. Losses were -35.71 million, -47.33% less than in 2024.
Financial numbers in ILS Financial StatementsNews
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company's p...
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing D...
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and...
InterCure receives noncompliance notification from Nasdaq
InterCure (INCR) announced that the company received a written notice from Nasdaq indicating that the company was not in compliance with Nasdaq Listing Rule 5450, as the company’s closing bid
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company receiv...
InterCure reports preliminary FY25 revenue NIS 265M
Adjusted EBITDA is expected to be positive in both the first and second halves of 2025, marking the Company’s twelfth consecutive half-year of positive Adjusted EBITDA. Cash on hand of
InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA.
InterCure, Cannasoul sign strategic investment, collaboration agreements
InterCure (INCR) announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D. The Share Purchase Agreement provides InterCure with a 28% owners...
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
Agreements formalize research partnership combining InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovation
InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive A...
InterCure reports 1H revenue NIS 130M vs. NIS 126M last year
Alexander Rabinovitch, CEO of InterCure (INCR), stated: “In the first half of 2025, InterCure delivered revenues of NIS 130 million, achieving positive Adjusted EBITDA for the eleventh consecutive hal...
InterCure announces acquisition of ISHI for 4.92M ordinary shares
InterCure (INCR) announced the strategic acquisition of Botanico, also known as ISHI, a premium medical cannabis technology and brand company that delivers immediate access to advanced cultivation tec...
InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
Acquisition of leading cannabis company marks major milestone in InterCure's commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025
2024 results were affected by damages to our southern facility caused by the terrorist attack on October 7, 2023, and the continued war in Gaza. InterCure is entitled to full compensation from the Is...
InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
InterCure (INCR) “announces that Mr. Ehud Barak will step down as Chairman of the board of directors of the Company, effective February 13, 2025. He will be succeeded by Mr.
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
NEW YORK and HERZLIYA, Israel , Feb. 12, 2025 /PRNewswire/ -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), announces today that Mr.
InterCure secures funding to support recovery of Nir Oz facility
InterCure (INCR) is pleased to announce that further to the company’s prior reports regarding the war-related damages and the reconstruction efforts of its facility in Kibbutz Nir Oz, the company
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
The funding may increase to NIS 107M to support the expansion of the facility in collaboration with the "Tkumah" administration, post-war. The funding includes investments from key shareholders of the...
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates.
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results ...
InterCure announces expansion of partnership with Cookies to Germany
InterCure is announcing a new strategic agreement with Cookies to cultivate, manufacture, import and distribute Cookies’ branded products, produced from its cultivation and manufacturing facilities, i...
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outsid...
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will part...
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts ...
InterCure Annual report: Q4 2023
InterCure has published its Q4 2023 annual report on May 1, 2024.